Blue Jet Healthcare Limited (BLUEJET) Earnings Call Transcripts

Blue Jet Healthcare Limited's Latest Earnings Call - Q4 FY2026

In Q4 FY '26, Blue Jet Healthcare Limited reported revenues of INR 235 crores, reflecting a 22% quarter-over-quarter increase but a 31% decline year-over-year. For the full fiscal year, revenues totaled INR 947 crores, down 8% from FY '25. Management highlighted strong growth in the Contrast Media segment, which saw a 91% increase year-over-year, while the PI/API segment faced challenges due to customer destocking. Looking ahead, management indicated improved visibility and expectations for double-digit growth in FY '27, particularly in the Contrast Media segment, supported by new product launches and a recovering PI segment.

Reported metrics

Guidance from management

Management expects double-digit growth in the Contrast Media segment for FY '27, supported by new product launches and improved order visibility in the PI segment. They anticipate continued investment in R&D and manufacturing capabilities.

What management said

And just to add on to that on the contrast media side, Thematically, we believe there are some select partnerships that we have on key molecules this translating into deeper partnerships. So we feel their optic requirements also increasing, and that's a combination of the existing molecules plus the launch of new molecules in FY '26.

See, if you look at Q4, majority of the turnover is from the existing customer, existing product. When you look at FY '27, whatever we have marketed, we have got, the forecast is quite encouraging. And we should be in a position to -- with a couple of new launches we are expecting, we do expect 1 or 2 validations and 1 commercial launch, which should actually like ensure that we will actually get into a sort of doubl...

What analysts pressed on

Analysts expressed concerns regarding the significant decline in the PI/API segment and the potential impact of customer destocking on future revenues. There were also questions about the timing and scale of new product launches and the overall demand outlook.

Main topics on the call

• Contrast Media Segment Growth — The Contrast Media segment reported a revenue of INR 193 crores in Q4, a 91% year-over-year increase. Management noted, "We expect 3 to 4 new product launches during the current year," indicating strong momentum in this ...
• PI/API Segment Challenges — The PI/API segment faced significant declines, with Q4 revenue dropping to INR 2.4 crores from INR 196 crores in Q4 FY '25. Management attributed this to "destocking by the customer," but expressed confidence in recovery...
• Investment in Growth Infrastructure — Management emphasized ongoing investments in R&D and manufacturing capabilities, particularly the Vizag greenfield project with a planned CapEx of INR 1,000 crores over three years. This is expected to enhance Blue Jet's...
• Future Growth Visibility — Management indicated improved visibility for FY '27, stating, "We believe the company is gradually transitioning from an investment and preparation phase into a broader commercialization and growth cycle."

Read the full Blue Jet Healthcare Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 6 Blue Jet Healthcare Limited earnings call transcripts on record, spanning August 7, 2024 to August 3, 2026. Based on this history, Blue Jet Healthcare Limited reports semi-annually. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BLUEJET

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

6

First call

August 7, 2024

Most recent

August 3, 2026

Reporting cadence

semi-annually